<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298713</url>
  </required_header>
  <id_info>
    <org_study_id>TAMRAD</org_study_id>
    <secondary_id>EUDRACT 2006-004332-79</secondary_id>
    <nct_id>NCT01298713</nct_id>
  </id_info>
  <brief_title>Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer</brief_title>
  <official_title>Phase 2 Study Assessing the Tolerance and Efficacy of Tamoxifen Alone Versus the Association Tamoxifen-RAD001 (Everolimus) in Patients With Anti-aromatase Resistant Breast Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tamoxifen is a classical treatment for breast metastatic cancer after 3rd generation&#xD;
      anti-aromatase hormonotherapy in adjuvant or in metastatic line. The Tamoxifen efficacy is&#xD;
      lowered by the hormonoresistance mechanisms due to the primary use of the anti-aromatases.&#xD;
      The Pi3K-AKT-mTor pathway is frequently associated to the hormonoresistance mechanisms. This&#xD;
      study is aimed to check if the inhibition of this signal transduction pathway by a synthetic&#xD;
      mTor inhibitor (Everolimus) could improve the efficacy of the Tamoxifen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2008</start_date>
  <completion_date type="Actual">September 12, 2018</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit at 24 weeks</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial and complete response per RECIST</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative toxicities</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>mTor Protein</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen 20mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen 20mg/d + RAD001 10mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>20mg daily (1 cap) until unbearable toxicity or progression</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10mg daily (2 caps of 5mg) until unbearable toxicity or progression</description>
    <arm_group_label>B</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Menopausal female patient aged &gt; 18 years&#xD;
&#xD;
          -  Histologically proven breast adenocarcinoma&#xD;
&#xD;
          -  ER and/or PR positive receptors and HER2 negative&#xD;
&#xD;
          -  previously received first or second line of hormonotherapy for metastatic disease&#xD;
&#xD;
          -  previously treated with anti-aromatase in adjuvant and/or in metastatic line&#xD;
&#xD;
          -  presence of one or several mesurable or evaluable metastatic lesion(s)&#xD;
&#xD;
          -  presence of at least one target lesion not previously irradiated&#xD;
&#xD;
          -  ECOG Performance status &lt; 2&#xD;
&#xD;
          -  adequate biological values&#xD;
&#xD;
          -  patient who has clearly given her consent by signing on informed consent form prior to&#xD;
             participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient with only local metastatic disease that can be treted by surgery&#xD;
&#xD;
          -  uncotrolled brain metastases, pulmonary carcinomatosal lymphangitis, hepatic&#xD;
             metastases&#xD;
&#xD;
          -  Previous treatment by Tamoxifen unless in adjuvant and terminated more than a year&#xD;
             before metastatic relapse&#xD;
&#xD;
          -  Patient with a tumor surexpressing HER2 that should be treated by trastuzumab&#xD;
&#xD;
          -  Patient that need an immediate local antalgic radiotherapy&#xD;
&#xD;
          -  Thrombo-embolism disease&#xD;
&#xD;
          -  serious concomitant pathology or uncontrolled that is susceptible to compromise the&#xD;
             participation in the study&#xD;
&#xD;
          -  history of another malignancy within past 5 years that could confound diagnosis or&#xD;
             staging of breast cancer (with the exception of in situ cacinoma of the cervix or&#xD;
             adequately treated basel cell carcinoma of the skin) and cancers cured for at least&#xD;
             for 5 years&#xD;
&#xD;
          -  patient with an history of significant cardiovascular impairment (congestive heart&#xD;
             failure&gt; NYHA grade II, unstable angina or myocardial infraction within the past six&#xD;
             months or serious cardiac arrhythmia)&#xD;
&#xD;
          -  patient with any medical or psychiatric condition that, in the opinion of the&#xD;
             Principal Investigator, would preclude her from participating in this study&#xD;
&#xD;
          -  patient with a known allergy to one or several of the study compounds&#xD;
&#xD;
          -  patients who may not be regularly available due to geographical, social or family&#xD;
             reasons&#xD;
&#xD;
          -  history of renal, hepatic or metabolic pathology that could preclude with metabolism&#xD;
             or elimination of the study product&#xD;
&#xD;
          -  deficiencies of the upper intestinal tract, malabsorption syndrome&#xD;
&#xD;
          -  patient who is pregnant, breast-feeding or using inadequate contraception&#xD;
&#xD;
          -  Treatment with experimental drugs (mTor inhibitor or tyrosin kinase inhibitor)&#xD;
&#xD;
          -  Patient treated with molecules that interfer with isoenzyme CYP3A&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bachelot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ARCAGY-GINECO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormonoresistance</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>Previously received anti-aromatase treatment</keyword>
  <keyword>mTor inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

